Johnson & Johnson (JNJ) Stock Forecast & Price Target

$252.93 +2.96 (+1.18%)

Closing price 07/17/2026 03:59 PM Eastern

Extended Trading

$253.41 +0.48 (+0.19%)

As of 07/17/2026 08:00 PM Eastern

Compare

Johnson & Johnson - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 26 Analyst Ratings

Sell
0

Hold
6

Buy
20

Based on 26 Wall Street analysts who have issued ratings for Johnson & Johnson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 6 have given a hold rating, 19 have given a buy rating, and 1 has given a strong buy rating for JNJ.

Consensus Price Target

$265.30
4.89% Upside

According to the 26 analysts' twelve-month price targets for Johnson & Johnson, the average price target is $265.30. The highest price target for JNJ is $305.00, while the lowest price target for JNJ is $210.00. The average price target represents a forecasted upside of 4.89% from the current price of $252.93.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for JNJ and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JNJ Analyst Ratings Over Time

Type	Current Forecast 7/19/25 to 7/19/26	1 Month Ago 6/19/25 to 6/19/26	3 Months Ago 4/20/25 to 4/20/26	1 Year Ago 7/19/24 to 7/19/25
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	19 Buy rating(s)	20 Buy rating(s)	18 Buy rating(s)	8 Buy rating(s)
Hold	6 Hold rating(s)	7 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$265.30	$253.04	$252.48	$172.87
Forecasted Upside	4.89% Upside	10.81% Upside	9.53% Upside	5.63% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

JNJ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

JNJ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Johnson & Johnson Stock vs. The Competition

Type	Johnson & Johnson	Medical Companies	Broader Market
Consensus Rating Score	2.81	2.29	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	4.89% Upside	877.81% Upside	14.09% Upside
News Sentiment Rating	Positive News See Recent JNJ News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
7/17/2026	Guggenheim 5 of 5 stars	Vamil Divan 5 of 5 stars	Reiterated Rating	Buy	$270.00	+8.13%
7/16/2026	Johnson Rice 2 of 5 stars		Upgrade	Outperform ➝ Buy	$280.00	+12.10%
7/16/2026	Scotiabank 4 of 5 stars		Reiterated Rating	Outperform	$305.00	+22.51%
7/16/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jayson Bedford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$258.00 ➝ $265.00	+4.69%
7/16/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$282.00	+13.92%
7/16/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$284.00 ➝ $294.00	+18.76%
7/16/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$263.00 ➝ $272.00	+9.88%
7/16/2026	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
7/15/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$260.00	+5.03%
7/13/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Nedelcovych Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$250.00 ➝ $300.00	+16.43%
Get the Latest News and Ratings for JNJ and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.
7/13/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$265.00 ➝ $287.00	+11.96%
7/10/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tim Anderson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$254.00 ➝ $263.00	+2.60%
7/8/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$285.00 ➝ $298.00	+11.47%
7/6/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Morten Herholdt Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$290.00	+11.89%
6/15/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy (B) ➝ Buy (B-)
5/13/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$265.00	+18.07%
4/16/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$240.00 ➝ $275.00	+15.87%
4/16/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$237.00 ➝ $246.00	+3.65%
4/15/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$234.00 ➝ $255.00	+6.19%
4/15/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$250.00 ➝ $260.00	+8.68%
4/15/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Market Perform	$225.00 ➝ $251.00	+4.92%
2/19/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$180.00 ➝ $210.00	-14.76%
1/27/2026	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ilya Zubkov Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$220.00	-2.28%
1/5/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Antalffy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
1/5/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$225.00 ➝ $240.00	+17.19%
12/11/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
7/23/2025	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy
7/17/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight
4/24/2025	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Todd Brooks Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
10/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight	$215.00 ➝ $215.00	+30.70%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:58 PM ET.

Should I Buy Johnson & Johnson Stock? JNJ Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, July 14, 2026. Please send any questions or comments about these Johnson & Johnson pros and cons to contact@marketbeat.com.

Johnson & Johnson
Bull Case

Here are some ways that investors could benefit from investing in Johnson & Johnson:

The company recently reported earnings per share (EPS) of $2.70, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
Johnson & Johnson has a robust net margin of 21.83%, suggesting efficient management and profitability, which can lead to higher returns for investors.
The firm has increased its quarterly dividend to $1.34, reflecting a commitment to returning value to shareholders, with an annualized dividend yield of approximately 2.1%.
With a return on equity of 32.60%, Johnson & Johnson demonstrates effective use of shareholder funds to generate profits, which is a positive indicator for potential investors.
The current stock price is around $241, which may present a favorable entry point for investors looking to capitalize on the company's growth trajectory.

Johnson & Johnson
Bear Case

Investors should be bearish about investing in Johnson & Johnson for these reasons:

The company reported a slight decrease in EPS compared to the same quarter last year, which may raise concerns about its growth sustainability.
Insider selling activity, such as the recent sale of 10,000 shares by an executive vice president, could signal a lack of confidence in the company's short-term prospects.
Despite a year-over-year revenue increase of 9.9%, the company faces ongoing challenges in the healthcare sector that could impact future performance.
The payout ratio of 61.97% indicates that a significant portion of earnings is being distributed as dividends, which may limit funds available for reinvestment in growth opportunities.
Institutional ownership is at 69.55%, which may lead to volatility if large investors decide to sell their positions, impacting stock price stability.

JNJ Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Johnson & Johnson is $265.30, with a high forecast of $305.00 and a low forecast of $210.00.

26 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 6 hold ratings, 19 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" JNJ shares.

According to analysts, Johnson & Johnson's stock has a predicted upside of 4.89% based on their 12-month stock forecasts.

Over the previous 90 days, Johnson & Johnson's stock had 4 upgrades and 2 downgrades by analysts.

Johnson & Johnson has been rated by research analysts at Bank of America, Citigroup, Freedom Capital, Guggenheim, HSBC, Johnson Rice, Leerink Partners, Morgan Stanley, Raymond James Financial, Royal Bank Of Canada, Scotiabank, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Johnson & Johnson more than other "medical" companies. The consensus rating for Johnson & Johnson is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how JNJ compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Johnson & Johnson Recommendations

This page (NYSE:JNJ) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Johnson & Johnson (JNJ) Stock Forecast & Price Target